Bomedemstat
- Generic Name
- Bomedemstat
- Drug Type
- Small Molecule
- Chemical Formula
- C28H34FN7O2
- CAS Number
- 1990504-34-1
- Unique Ingredient Identifier
- Y2T4ALDEAT
Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06596668
- Locations
- 🇺🇸
Celerion, Inc. ( Site 0001), Tempe, Arizona, United States
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
- Conditions
- Essential Thrombocythemia
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06456346
- Locations
- 🇪🇸
Clinica Universidad de Navarra-Hematology Department ( Site 0485), Madrid, Madrid, Comunidad De, Spain
🇪🇸Hospital Universitario Ramón y Cajal-Hematology ( Site 0484), Madrid, Madrid, Comunidad De, Spain
🇪🇸Hospital Costa del Sol-Hematology Service ( Site 0493), Marbella, Malaga, Spain
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
- Conditions
- Thrombocythemia, EssentialPrimary MyelofibrosisMyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPolycythemia Vera
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 400
- Registration Number
- NCT06351631
- Locations
- 🇺🇸
DUHS Duke Blood Cancer Center ( Site 6005), Durham, North Carolina, United States
🇺🇸University of Michigan ( Site 6000), Ann Arbor, Michigan, United States
🇺🇸UPMC Hillman Cancer Center ( Site 6004), Pittsburgh, Pennsylvania, United States
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
- Conditions
- Essential Thrombocythemia
- Interventions
- Drug: Interferon alfa/pegylated interferon alfa
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 300
- Registration Number
- NCT06079879
- Locations
- 🇺🇸
Los Angeles Cancer Network ( Site 3491), Glendale, California, United States
🇺🇸Stanford Cancer Institute ( Site 0107), Stanford, California, United States
🇺🇸The Lundquist Institute ( Site 3423), Torrance, California, United States
Venetoclax and Bomedemstat in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia, in Relapse
- Interventions
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Terrence J Bradley, MD
- Target Recruit Count
- 18
- Registration Number
- NCT05597306
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 40
- Registration Number
- NCT05569538
- Locations
- ðŸ‡ðŸ‡°
Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
A Study of Bomedemstat (MK-3543) in Participants With Polycythemia Vera (MK-3543-004)
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Target Recruit Count
- 20
- Registration Number
- NCT05558696
- Locations
- 🇺🇸
BRCR Global ( Site 0120), Plantation, Florida, United States
🇺🇸Hematology Oncology of the North Shore ( Site 0104), Skokie, Illinois, United States
🇺🇸Ohio State University Comprehensive Cancer Center ( Site 0103), Columbus, Ohio, United States
Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005)
- Conditions
- Thrombocythemia, EssentialPrimary Myelofibrosis
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Target Recruit Count
- 80
- Registration Number
- NCT05223920
- Locations
- 🇦🇺
Gold Coast Hospital and Health Service, Southport, Queensland, Australia
🇬🇧Guy's and Saint Thomas' NHS Foundation Trus, London, United Kingdom
🇺🇸University of Miami Leonard M. Miller, Miami, Florida, United States
Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
- Conditions
- Limited Stage Lung Small Cell CarcinomaExtensive Stage Lung Small Cell Carcinoma
- Interventions
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3
- Registration Number
- NCT05191797
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Target Recruit Count
- 73
- Registration Number
- NCT04254978
- Locations
- 🇳🇿
Middlemore Hospital, Auckland, New Zealand
🇩🇪Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), Essen, Germany
🇬🇧Guys and St Thomas Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.